ICON plc vs ICON

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/iconplc/kcrcro

Category	ICON plc	ICON
Listed site	cro	cro
Summary	ICON is a world-leading clinical research organization providing outsourced services across the full clinical trial lifecycle, from early phase through commercialization, to pharmaceutical, biotechnology, and medical device companies.	ICON is a CRO with 8,000 biotech-dedicated professionals offering end-to-end clinical development, consulting, and therapeutic expertise across all development phases.
Services	Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Clinical Operations Clinical Trial Services Clinical Imaging Core Lab Central Laboratory Services Data Management & eClinical Biostatistics & Statistical Programming Medical Writing Pharmacovigilance & Drug Safety Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy Flow Cytometry Services Bioanalysis Translational Research Biomarker Assays Immunogenicity Assays (ADA / NAb) Ligand-Binding Bioanalysis (Large Molecule) LC-MS Bioanalysis (Small Molecule) Cardiovascular & Metabolic Specialty Services CNS Specialty Services Oncology Specialty Services Immunology & Inflammation Services Companion Diagnostics Development Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy	Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Clinical Operations Clinical Trial Services Clinical Imaging Core Lab Central Laboratory Services US FDA Regulatory Strategy EU EMA Regulatory Strategy Regulatory Affairs Medical Writing Cardiovascular & Metabolic Specialty Services CNS Specialty Services Oncology Specialty Services Immunology & Inflammation Services Virology Services Biostatistics & Statistical Programming Data Management & eClinical Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy Translational Research
Modalities	Small Molecule Biologics (Monoclonal Antibodies) Biologics (Other) Cell Therapy Gene Therapy Vaccine	Biologics (Monoclonal Antibodies) Biologics (Other) Cell Therapy Gene Therapy Vaccine
Indications	Cardiovascular Neurology Immunology Oncology Infectious Disease Metabolic Rare Disease Women's Health Ophthalmology	Oncology Neurology Metabolic Cardiovascular Infectious Disease Rare Disease Women's Health
Locations	Headquarters, Dublin, Ireland Belgium, Belgium, Belgium Bulgaria, Bulgaria, Bulgaria Germany, Germany, Germany Hungary, Hungary, Hungary Italy, Italy, Italy Netherlands, Netherlands, Netherlands Poland, Poland, Poland Romania, Romania, Romania Slovakia, Slovakia, Slovakia South Africa, South Africa, South Africa Spain, Spain, Spain Türkiye, Türkiye, Türkiye United Kingdom, United Kingdom, United Kingdom Australia, Australia, Australia China, China, China India, India, India Japan, Japan, Japan Korea, Korea, Korea Malaysia, Malaysia, Malaysia Taiwan, Taiwan, Taiwan Argentina, Argentina, Argentina Brazil, Brazil, Brazil Chile, Chile, Chile Colombia, Colombia, Colombia Mexico, Mexico, Mexico Belgium, Belgium, Belgium Bulgaria, Bulgaria, Bulgaria Germany, Germany, Germany Hungary, Hungary, Hungary Italy, Italy, Italy Netherlands, Netherlands, Netherlands Poland, Poland, Poland Romania, Romania, Romania Slovakia, Slovakia, Slovakia South Africa, South Africa, South Africa Spain, Spain, Spain Türkiye, Türkiye, Türkiye United Kingdom, United Kingdom, United Kingdom Australia, Australia, Australia China, China, China India, India, India Japan, Japan, Japan Korea, Korea, Korea Malaysia, Malaysia, Malaysia Taiwan, Taiwan, Taiwan Argentina, Argentina, Argentina Brazil, Brazil, Brazil Chile, Chile, Chile Colombia, Colombia, Colombia Mexico, Mexico, Mexico United States, United States, United States	Data not yet provided.
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.